Tiziana announces presentation of six-month safety and biomarker data for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-spms) at the ectrims annual congress

Late-breaking poster to be presented titled: “treatment of six non-active secondary progressive ms with nasal anti-cd3 monoclonal antibody (foralumab): safety, biomarker, and disability outcomes” new york, oct. 11, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a late breaking poster titled, “treatment of six non-active secondary progressive ms with nasal anti-cd3 monoclonal antibody (foralumab): safety, biomarker, and disability outcomes”, will be presented at the 39th congress of the european committee for treatment and research of multiple sclerosis (ectrims) being held in milan, italy, october 11-13, 2023.
TLSA Ratings Summary
TLSA Quant Ranking